West Pharmaceutical Services (WST) Gains from Investment Securities (2009 - 2026)

West Pharmaceutical Services has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$1.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$1.0 million, down 140.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.5 million (up 76.67% YoY), and the FY2024 annual result was $5.7 million, down 60.14% from the prior year.
• Gains from Investment Securities came in at -$1.0 million for Q1 2026 at West Pharmaceutical Services, down from -$800000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $25.9 million in Q4 2023 to a low of -$17.5 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $100000.0 (2024), against an average of $2.3 million.
• Across the five-year window, Gains from Investment Securities slumped 167.57% in 2024 and jumped 2400.0% in 2025, its largest moves.
• West Pharmaceutical Services' Gains from Investment Securities stood at -$1.3 million in 2022, then soared by 2092.31% to $25.9 million in 2023, then plunged by 167.57% to -$17.5 million in 2024, then surged by 95.43% to -$800000.0 in 2025, then declined by 25.0% to -$1.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$1.0 million (Q1 2026), -$800000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.